362 related articles for article (PubMed ID: 25504326)
21. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
22. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
Ranum LP; Day JW
Curr Neurol Neurosci Rep; 2002 Sep; 2(5):465-70. PubMed ID: 12169228
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
24. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
26. Mass spectrometry analysis of complexes formed by myotonic dystrophy protein kinase (DMPK).
Forner F; Furlan S; Salvatori S
Biochim Biophys Acta; 2010 Jun; 1804(6):1334-41. PubMed ID: 20188867
[TBL] [Abstract][Full Text] [Related]
27. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic mechanisms of myotonic dystrophy.
Lee JE; Cooper TA
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1281-6. PubMed ID: 19909263
[TBL] [Abstract][Full Text] [Related]
29. Expression of MBNL and CELF mRNA transcripts in muscles with myotonic dystrophy.
Nezu Y; Kino Y; Sasagawa N; Nishino I; Ishiura S
Neuromuscul Disord; 2007 Apr; 17(4):306-12. PubMed ID: 17331722
[TBL] [Abstract][Full Text] [Related]
30. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
31. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
[TBL] [Abstract][Full Text] [Related]
32. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients.
Botta A; Rinaldi F; Catalli C; Vergani L; Bonifazi E; Romeo V; Loro E; Viola A; Angelini C; Novelli G
J Med Genet; 2008 Oct; 45(10):639-46. PubMed ID: 18611984
[TBL] [Abstract][Full Text] [Related]
33. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
[TBL] [Abstract][Full Text] [Related]
34. Dynamics and variability of transcriptomic dysregulation in congenital myotonic dystrophy during pediatric development.
Hale MA; Bates K; Provenzano M; Johnson NE
Hum Mol Genet; 2023 Apr; 32(9):1413-1428. PubMed ID: 36222125
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on gene therapy in myotonic dystrophy type 1.
Magaña JJ; Cisneros B
J Neurosci Res; 2011 Mar; 89(3):275-85. PubMed ID: 21259315
[TBL] [Abstract][Full Text] [Related]
36. Tackling the pathogenesis of RNA nuclear retention in myotonic dystrophy.
Mastroyiannopoulos NP; Shammas C; Phylactou LA
Biol Cell; 2010 Jul; 102(9):515-23. PubMed ID: 20690904
[TBL] [Abstract][Full Text] [Related]
37. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.
Wheeler TM; Krym MC; Thornton CA
Neuromuscul Disord; 2007 Mar; 17(3):242-7. PubMed ID: 17306536
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
Morriss GR; Rajapakshe K; Huang S; Coarfa C; Cooper TA
Hum Mol Genet; 2018 Aug; 27(16):2789-2804. PubMed ID: 29771332
[TBL] [Abstract][Full Text] [Related]
39. The hallmarks of myotonic dystrophy type 1 muscle dysfunction.
Ozimski LL; Sabater-Arcis M; Bargiela A; Artero R
Biol Rev Camb Philos Soc; 2021 Apr; 96(2):716-730. PubMed ID: 33269537
[TBL] [Abstract][Full Text] [Related]
40. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
Kuyumcu-Martinez NM; Wang GS; Cooper TA
Mol Cell; 2007 Oct; 28(1):68-78. PubMed ID: 17936705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
